The quality of evidence used in manufacturers’ submissions for technology appraisal (TA) is an important factor in receiving a positive recommendation from health technology assessment (HTA) bodies. In the absence of evidence from head-to-head randomised controlled trials (RCTs), National Institute for Health and Care Excellence (NICE) guidelines recommend the use of indirect comparison (IC) and network meta-analysis (NMA). In the sixth edition of our DRG investigative series, we assess the use of ICs/NMAs in HTA submissions and identify common criticisms highlighted by NICE and Evidence Review Groups (ERGs).

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now